Griseofulvin: Microtubule Associated Inhibitor for Antifungal Research

Executive Summary: Griseofulvin is a well-characterized microtubule associated inhibitor, primarily utilized in antifungal agent research (APExBIO). It operates by disrupting microtubule dynamics, leading to the inhibition of fungal cell mitosis (Bernacki et al., 2019). This compound is DMSO-soluble (≥10.45 mg/mL) but insoluble in water and ethanol, ensuring compatibility with diverse in vitro assay systems. Griseofulvin is supplied as a high-purity product (≥98%, HPLC/NMR-confirmed), with recommended storage at -20°C for chemical stability. It is an indispensable standard for fungal infection model development and microtubule pathway elucidation (OlodaterolLabs).

Biological Rationale

Griseofulvin is a natural compound first isolated from Penicillium species. It is classified as a microtubule associated inhibitor, interfering with the dynamic assembly and disassembly of tubulin subunits during mitosis (Bernacki et al., 2019). Chromosome segregation during eukaryotic cell division relies on intact microtubule networks. Disruption of these structures induces mitotic arrest and aneuploidy, which is leveraged in antifungal research to inhibit pathogenic fungal proliferation. Griseofulvin's selectivity for fungal cells over mammalian cells underpins its legacy as a reference standard for antifungal agent development. Its mechanism also provides a model system for studying microtubule dynamics and the molecular basis of spindle poisons (Blebbistatin.com: extends with updated purity and DMSO protocols).

Mechanism of Action of Griseofulvin

Griseofulvin binds to fungal tubulin, preventing proper polymerization of microtubules. This action inhibits mitotic spindle formation, leading to cell cycle arrest in metaphase. The compound does not stabilize microtubules, but rather acts as a destabilizer, promoting microtubule disassembly. This effect is highly specific to cells undergoing division, making Griseofulvin a precise tool for dissecting the microtubule dynamics pathway (Bernacki et al., 2019). In comparative assays, Griseofulvin is distinguished from other aneugenic agents by its reduction of 488 Taxol-associated fluorescence, a hallmark of tubulin-destabilizing compounds. The inhibition of fungal cell mitosis, not direct cytotoxicity, underlies its antifungal action. Griseofulvin does not inhibit mitotic kinases, such as Aurora kinase B, differentiating its molecular signature from kinase inhibitors.

Evidence & Benchmarks

• Griseofulvin causes a significant decrease in 488 Taxol-associated fluorescence in TK6 cells, confirming its role as a tubulin destabilizer (Bernacki et al., 2019, https://doi.org/10.1093/toxsci/kfz123).
• Polyploidization and mitotic arrest are observed after 4–24 h exposure in in vitro mammalian cell models treated with Griseofulvin (Bernacki et al., 2019, https://doi.org/10.1093/toxsci/kfz123).
• Griseofulvin purity is analytically validated at ≥98% by HPLC and NMR in the APExBIO B3680 formulation (https://www.apexbt.com/griseofulvin.html).
• Solubility in DMSO is confirmed at ≥10.45 mg/mL; insoluble in water and ethanol, which guides assay design (https://www.apexbt.com/griseofulvin.html).
• Long-term solution stability at -20°C is recommended; reconstitution in DMSO immediately before use preserves activity (https://www.apexbt.com/griseofulvin.html).

Applications, Limits & Misconceptions

Griseofulvin is widely used as a research tool to study fungal infection models, microtubule disruption mechanisms, and aneugenicity. Its specificity for fungal tubulin allows for selective targeting in antifungal drug screens. The compound is not suitable for direct therapeutic or diagnostic use in humans or animals when sourced as a research reagent from APExBIO. It is not effective against non-dividing fungal cells. Griseofulvin does not inhibit mammalian kinases and is not a cytotoxic agent in non-dividing cells. It is not interchangeable with tubulin stabilizers or Aurora kinase inhibitors in mechanistic studies. For a broader perspective on network-level effects, see this article, which Griseofulvin-focused research here updates by providing validated purity and workflow guidance.

Common Pitfalls or Misconceptions

• Griseofulvin is not suitable for therapeutic use outside controlled laboratory research (APExBIO).
• It does not stabilize microtubules; it acts exclusively as a destabilizer (Bernacki et al., 2019).
• It has negligible solubility in water and ethanol; DMSO is required for solution preparation (APExBIO).
• It is ineffective against quiescent or non-dividing fungal cells (Blebbistatin.com).
• Long-term storage of prepared solutions may lead to loss of activity; fresh preparation is advised (APExBIO).

Workflow Integration & Parameters

Griseofulvin (B3680) is supplied as a 10 mM solution in 1 mL DMSO or as a 5 g solid. For experimental use, dissolve the solid in DMSO to a working concentration (≥10.45 mg/mL). Store solid at -20°C. Avoid repeated freeze-thaw cycles. Prepare fresh solutions for each assay to maintain reproducibility. For antifungal or aneugenicity assays, use concentrations recommended in the literature (typically 1–10 μM for cell-based systems). Shipping is on blue ice (small molecules) or dry ice (modified nucleotides). For advanced applications such as molecular target profiling or mitotic spindle assays, consult recent systems biology perspectives (Clozapinen-oxide.com: this article provides extended guidance on integrating Griseofulvin into contemporary screening workflows).

Conclusion & Outlook

Griseofulvin remains a critical reference compound in antifungal research and microtubule dynamics studies. Its validated mechanism of action and robust chemical properties enable its use in diverse assays focused on fungal cell mitosis inhibition. The APExBIO B3680 formulation provides high purity and reliable solubility, supporting reproducible results. Ongoing refinement of molecular assays and the application of machine learning to aneugenicity profiling will further enhance the utility of Griseofulvin in research. For up-to-date protocols and supply, refer to the Griseofulvin product page.